Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 19/20 | 0.66 |
| ▸ | JAK2 | O60674 | 11/20 | 0.66 |
| ▸ | TYK2 | P29597 | 2/20 | 0.66 |
| ▸ | JAK3 | P52333 | 2/20 | 0.66 |
| ▸ | AURKA | O14965 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15058427 | 1.00 | JAK1 (0.66) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL15056081 | 0.95 | JAK1 (0.64) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL15056079 | 0.95 | JAK1 (0.64) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL15056548 | 0.95 | JAK1 (0.64) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL15058422 | 0.88 | JAK1 (0.56) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL16336787 | 0.88 | JAK1 (0.56) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL15056494 | 0.88 | JAK1 (0.61) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL15072144 | 0.88 | JAK1 (0.61) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL15060023 | 0.88 | JAK1 (0.61) | JAK1JAK2TYK2JAK3AURKA | |
| SCHEMBL15056223 | 0.87 | JAK1 (0.54) | JAK1JAK2TYK2JAK3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2015-01-01 | — | — | US | claimed |
| EP-2794598-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2014-10-29 | — | — | EP | claimed |
| WO-2013092854-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2013-06-27 | — | — | WO | claimed |
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | JAK2, JAK1, JAK3 | JAK1 2/4885JAK2 1/4885TYK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.